Home › Funds › BAKER BROS. ADVISORS LP › DSGN
BAKER BROS. ADVISORS LP position in DSGN
DESIGN THERAPEUTICS INC · Health Care
BAKER BROS. ADVISORS LP reported holding 2,678,430 shares of DSGN (DESIGN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$38.8M, representing 0.20% of its reported portfolio and ranking #41 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed DSGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's DSGN position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in DSGN in Q3 2023 at 1,500,000 shares (US$3.5M). The position peaked in Q2 2026 at 2,678,430 shares, worth US$38.8M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 2,678,430 shares valued at US$38.8M — an increase of 92,452 shares quarter over quarter.. Notable position changes include a 30% increase in Q4 2025 (shares rose 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.50M | $3.54M | New |
| Q4 2023 | 1.50M | $3.98M | Hold |
| Q1 2024 | 1.66M | $6.70M | Add |
| Q2 2024 | 1.70M | $5.68M | Add |
| Q3 2024 | 1.74M | $9.38M | Add |
| Q4 2024 | 1.74M | $10.76M | Hold |
| Q1 2025 | 1.74M | $6.73M | Hold |
| Q2 2025 | 1.71M | $5.77M | Reduce |
| Q3 2025 | 1.71M | $12.90M | Hold |
| Q4 2025 | 2.23M | $20.95M | Add |
| Q1 2026 | 2.59M | $27.51M | Add |
| Q2 2026 | 2.68M | $38.76M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DSGN and 13F data
DSGN (DESIGN THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in DSGN — the largest reported positions include SR ONE CAPITAL MANAGEMENT, LP (US$94.4M), Logos Global Management LP (US$43.4M), Trails Edge Capital Partners, LP (US$29.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DSGN
- SR ONE CAPITAL MANAGEMENT, LP 6.53M sh · $94.44M · Q2 2026
- Logos Global Management LP 3.00M sh · $43.41M · Q2 2026
- Trails Edge Capital Partners, LP 2.00M sh · $28.96M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.81M sh · $26.19M · Q2 2026
- Vivo Capital, LLC 1.61M sh · $23.34M · Q2 2026
- Almitas Capital LLC 1.03M sh · $14.86M · Q2 2026
- Sofinnova Investments, Inc. 865.13K sh · $12.52M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 282.56K sh · $4.09M · Q2 2026
- KVP Capital Advisors, LP 185.00K sh · $2.68M · Q2 2026
- Elmind Capital, LP 107.90K sh · $1.56M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held DSGN?
BAKER BROS. ADVISORS LP has disclosed DSGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in DSGN?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.68M shares of DSGN (DESIGN THERAPEUTICS INC), valued at $38.76M, representing 0.20% of its reported portfolio and ranking #41.
Has BAKER BROS. ADVISORS LP been buying or selling DSGN?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP increased its position in DSGN. The position peaked in Q2 2026 at 2.68M shares.
Which other funds hold DSGN?
Other major institutional holders of DSGN include SR ONE CAPITAL MANAGEMENT, LP, Logos Global Management LP, Trails Edge Capital Partners, LP, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.